Viridian Therapeutics, Inc.\DE (VRDN) Interest & Investment Income (2018 - 2026)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Interest & Investment Income came in at $7.9 million in Q1 2026, up 2987.06% year-on-year from $255000.0 in Q1 2025, and down 70.87% quarter-over-quarter from $27.0 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Interest & Investment Income (2018 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Interest & Investment Income history runs 9 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 2987.06% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $40.2 million, a 149.74% increase from a year earlier, with the FY2025 full-year figure at $27.4 million, down 13.29% from the prior year.
- Interest & Investment Income fell to $7.9 million in Q1 2026 per VRDN's latest filing, from $27.0 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $27.0 million in Q4 2025 and bottomed at -$12.3 million in Q4 2023.
- The 5-year median for Interest & Investment Income is $3.4 million (2022), against an average of $3.6 million.
- Across the five-year window, Interest & Investment Income tumbled 456.65% in 2023 and surged 2987.06% in 2026, its largest moves.
- Year by year, Interest & Investment Income stood at $3.4 million in 2022, then tumbled by 456.65% to -$12.3 million in 2023, then surged by 169.26% to $8.5 million in 2024, then jumped by 217.21% to $27.0 million in 2025, then sank by 70.87% to $7.9 million in 2026.
- Per Business Quant, the three latest VRDN Interest & Investment Income figures stand at $7.9 million (Q1 2026), $27.0 million (Q4 2025), and $5.5 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 655.26 Mn | 655.26 Mn | - | 7.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.87 Mn |
| Dec 31, 2025 | 27.03 Mn |
| Sep 30, 2025 | 5.52 Mn |
| Jun 30, 2025 | -176,000.00 |
| Mar 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 8.52 Mn |
| Sep 30, 2024 | 7.52 Mn |
| Jun 30, 2024 | -176,000.00 |
| Mar 31, 2024 | -705,000.00 |
| Dec 31, 2023 | -12.30 Mn |
| Sep 30, 2023 | 4.16 Mn |
| Jun 30, 2023 | 4.38 Mn |
| Mar 31, 2023 | 4.49 Mn |
| Dec 31, 2022 | 3.45 Mn |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 227,000.00 |
| Mar 31, 2022 | 196,000.00 |
| Dec 31, 2021 | 138,000.00 |
| Sep 30, 2021 | 91,000.00 |
| Jun 30, 2021 | 34,000.00 |